JATT vs. CCCC, JSPR, TNYA, AURA, TRML, MGTX, STRO, AVXL, REPL, and SOPH
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include C4 Therapeutics (CCCC), Jasper Therapeutics (JSPR), Tenaya Therapeutics (TNYA), Aura Biosciences (AURA), Tourmaline Bio (TRML), MeiraGTx (MGTX), Sutro Biopharma (STRO), Anavex Life Sciences (AVXL), Replimune Group (REPL), and SOPHiA GENETICS (SOPH). These companies are all part of the "biological products, except diagnostic" industry.
JATT Acquisition (NYSE:JATT) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.
C4 Therapeutics received 25 more outperform votes than JATT Acquisition when rated by MarketBeat users.
JATT Acquisition has a net margin of 0.00% compared to C4 Therapeutics' net margin of -629.24%. JATT Acquisition's return on equity of -49.58% beat C4 Therapeutics' return on equity.
JATT Acquisition has higher earnings, but lower revenue than C4 Therapeutics.
In the previous week, C4 Therapeutics had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for C4 Therapeutics and 0 mentions for JATT Acquisition. C4 Therapeutics' average media sentiment score of 1.18 beat JATT Acquisition's score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the news media.
48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 8.0% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
C4 Therapeutics has a consensus target price of $10.11, suggesting a potential upside of 84.51%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than JATT Acquisition.
Summary
C4 Therapeutics beats JATT Acquisition on 7 of the 12 factors compared between the two stocks.
Get JATT Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
